Novartis
-
For the global support of eye care professionals, Alcon launched Alcon Experience Academy
Sep 19, 2018Alcon, the global leader in eye care and a division of Novartis, is expanding its extensive, global support of eye care professionals through the unveiling of the Alcon Experience Academy. The robust program offers face-to-face training... -
Alcon to locate its future global headquarters in Switzerland, ahead of proposed spinoff from Novartis
Sep 11, 2018Alcon, the global leader in eye care and a division of Novartis, today announced plans to locate its future global headquarters in the Canton of Geneva, Switzerland, following completion of its proposed spinoff from Novartis. Alcon’s... -
Novartis appoints Dr. Klaus Moosmayer as Chief Ethics Risk and Compliance Officer
Aug 21, 2018Novartis announced the appointment of Dr Klaus Moosmayer as Chief Ethics, Risk and Compliance Officer. He will report to Vas Narasimhan, M.D., CEO of Novartis and become a member of the Executive Committee of Novartis (ECN).... -
Novartis to cut loose its Alcon eye care division and aimed to buy back $5.0 billion of its own shares
Jun 29, 2018Swiss pharmaceutical giant Novartis said Friday it planned to cut loose its Alcon eye care division, and aimed to buy back $5.0 billion of its own shares by the end of 2019. Novartis said that by... -
Novartis successfully completes the acquisition of AveXis Inc
May 16, 2018Novartis AG announced that it has completed the acquisition of AveXis, Inc. through the consummation of a merger of its indirect wholly-owned subsidiary, Novartis AM Merger Corporation, with and into AveXis without a vote of the... -
Novartis launches FocalView app
Apr 25, 2018Novartis announced the launch of its FocalView app, an ophthalmic digital research platform created with ResearchKit. FocalView aims to allow researchers to track disease progression by collecting real-time, self-reported data directly from consenting patients. By adapting... -
Novartis teams up with Harvard to develop next generation biomaterial systems to deliver immunotherapies
Mar 22, 2018Novartis announced that it is teaming up with scientists from the Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber Cancer Institute to develop biomaterial systems for its portfolio of immuno-oncology therapies. The... -
Novartis expands alliance with Science 37 to advance virtual clinical trials program
Mar 9, 2018The studies will blend virtual and traditional models, with increasing degrees of decentralization towards a mostly “site-less” model. Novartis was an early investor in Science 37 and together we have already initiated virtual trials for a cluster... -
Novartis forms alliance to develop medicines for treating infectious diarrheal disease
Feb 21, 2018Diarrheal diseases are one of the leading causes of childhood mortality globally, resulting in approximately 525,000 deaths each year and cryptosporidiosis is the second leading cause of infectious diarrhea in children under 2 years of age.... -
Novartis exclusively licenses first ophthalmology gene therapy in all markets outside the US
Jan 25, 2018The market authorization application (MAA) with the European Medicines Agency (EMA) was filed on July 31, 2017. Currently, there is no existing therapy for this disease outside the US. Novartis announced a licensing agreement with Spark...
